FDA to Approve Pfizer COVID-19 Vaccine for Ages 12-15 by Next Week

Headline Roundup May 3rd, 2021

The U.S. Food and Drug Administration (FDA) is expected to grant emergency use authorization of the Pfizer COVID-19 vaccine to children as young as 12 by next week, the New York Times first reported Monday. If the FDA approves the decision, the Centers for Disease Control and Prevention's (CDC) advisory panel will likely meet the day after to make recommendations for the shots’ use in teens. In March, Pfizer submitted data from a trial of nearly 2,300 adolescents between 12 and 15 years old, half of whom received the same two-shot regimen that has proven effective in adults. The trial's results suggested the two-shot vaccination process offered similar protection to adolescents as it does to adults. Vaccination approval for younger people is awaited by those who want to get students back to in-person school by the start of the new school year. The authorization could come by the end of the week.

The story received wide coverage from across the political spectrum.

FDA to Approve Pfizer COVID-19 Vaccine for Ages 12-15 by Next Week

From the Center
13320

The U.S. Food and Drug Administration is preparing to authorize Pfizer Inc and German partner BioNTech SE’s COVID-19 vaccine for adolescents aged between 12 and 15 years by early next week, the New York Times reported on Monday, citing federal officials familiar with the agency’s plans. An approval is highly anticipated after the drugmakers said in March that the vaccine was found to be safe, effective and produced robust antibody responses in 12- to 15-year-olds in a clinical trial.

Responding to a Reuters request for comment, the FDA said its...

Read full story
From the Right
13320

The Food and Drug Administration is expected to authorize the use of the Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12 to 15 by early next week, according to a new report.

The authorization could come as soon as the end of this week, the New York Times reported on Monday. If the FDA gives the green light, the Centers for Disease Control and Prevention’s advisory panel will likely convene the next day to review the clinical trial data and make recommendations for the shots’ use in adolescents, the report says.

Read full story
Some content from this outlet may be limited or behind a paywall.
From the Left
13320

The Food and Drug Administration is expected by next week to grant expanded emergency use authorization to allow children as young as 12 to receive the coronavirus vaccine developed by Pfizer and German firm BioNTech, according to three federal officials familiar with the situation.

The agency is still working on the authorization, said the officials, who spoke on the condition of anonymity to speak freely. Shortly after the FDA decision, a Centers for Disease Control and Prevention advisory committee is expected to meet to recommend how the vaccine should be...

Read full story
Some content from this outlet may be limited or behind a paywall.

AllSides Talks

Learn more about AllSides Talks